You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical Function

Article metrics

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Poster Presentations. Psoriatic arthritis
SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical Function

 

Online download statistics by month:

Online download statistics by month: June 2014 to March 2024

AbstractFullPdf
Jun 2014200
Jul 20141800
Aug 20141402
Sep 2014800
Oct 20143004
Nov 20143901
Dec 20141101
Jan 20151600
Feb 20151301
Mar 20151503
Apr 2015300
May 2015801
Jun 2015401
Jul 2015402
Aug 2015901
Sep 2015301
Oct 2015400
Nov 2015903
Dec 2015201
Jan 2016502
Feb 2016701
Mar 2016602
Apr 20161304
May 20161901
Jun 20161102
Jul 2016800
Aug 20161200
Sep 20161801
Oct 201629020
Nov 20161402
Dec 20161100
Jan 20172505
Feb 20171903
Mar 20173409
Apr 20171604
May 20172301
Jun 20171501
Jul 2017800
Aug 20172001
Sep 20176203
Oct 20173001
Nov 20175004
Dec 20172401
Jan 20186001
Feb 20189704
Mar 20187407
Apr 20187603
May 20183803
Jun 20181801
Jul 20183200
Aug 20184200
Sep 20182400
Oct 20182000
Nov 20183601
Dec 2018200
Jan 20191500
Feb 2019400
Mar 20191000
Apr 20191400
May 2019400
Jun 2019800
Jul 2019600
Sep 2019200
Oct 20191200
Feb 2020400
Mar 20201000
Apr 2020400
Jul 2020400
Sep 2020800
Oct 20201000
Nov 2020400
Dec 2020400
Jan 2021801
Mar 2021200
Apr 2021200
May 2021600
Oct 20211000
Nov 20211000
Dec 20211000
Jan 2022400
Feb 2022200
Mar 20221000
May 20221400
Jul 20222200
Aug 20221000
Sep 2022200
Oct 2022400
Nov 20221600
Dec 2022800
Jan 2023200
Feb 2023400
Mar 2023200
May 2023200
Jul 2023200
Aug 2023600
Sep 20231000
Nov 2023200
Dec 20231000
Jan 2024800
Feb 2024200
Mar 2024200
Total15250111